U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473154) titled 'Controlling Hyperactive Immunity With Long-lived Lymphocytes' on Feb. 27.
Brief Summary: This study is a Phase 1/2, open-label clinical trial to test an experimental treatment called QEL-005 in adults with two autoimmune conditions: diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid arthritis (D2TRA). The main goals are to find out whether QEL-005 is safe, how well people tolerate it, and whether it may help reduce disease activity or improve symptoms.
QEL-005 is made from a participant's own white blood cells (autologous cells). These cells are collected and then changed in a laboratory using genetic m...